glp 1 incretin effect A pathophysiological update of the incretins In patients with #obesity, incretin-based

This investigation utilizes the FAERS database to conduct a large-scale pharmacoepidemiologic analysis, aiming to generate robust real-world evidence regarding the safety profile of GLP-1 receptor agonist and metformin combination therapy through systematic evaluation of reported adverse events

HbA1c: Hemoglobin A1c

We excluded patients who had any evidence of T2D

Statistical Analysis Descriptive statistics were used to summarize baseline characteristics and outcomes

The whole set of miRNAs for a given genome is called the miRNome

We also examined the possibility of surveillance bias, where GLP-1 RA users could have had more encounters, leading to faster diagnoses of cirrhosis and complications, and found no evidence of this